COVID-19和肺高血压:一个有趣的动态
Saam Foroshani1, Michael Airo1, Avi Levine2
1From the Department of Medicine, New York Medical College, Valhalla, NY.
Cardiology in review
|February 24, 2024
概括
由于诸如细胞因子风暴和肺损伤等因素,COVID-19感染可能会增加患肺高血压 (PH) 的风险. 现有患有COVID-19的PH患者可能面临独特的结果,并且正在探索PH治疗COVID-19并发症.
科学领域:
- 心脏病学和肺病学.
- 传染性疾病 传染性疾病
- 关键护理医学 关键护理医学
背景情况:
- 自2020年以来,COVID-19和肺高血压 (PH) 之间的关系一直是越来越多的研究领域.
- 虽然PH病理生理学已被理解,但COVID-19的多系统性影响,特别是对心肺系统的影响,仍在出现.
- 研究兴趣集中在SARS-CoV-2感染与PH发展和结果之间的相互作用上.
研究的目的:
- 审查目前对COVID-19和肺高血压之间的相互作用的理解.
- 为了检查发展PH后SARS-CoV-2感染的风险因素.
- 讨论COVID-19感染了先前存在的PH患者的结果,并探索PH药物的潜在治疗应用在COVID-19患者中.
主要方法:
- 文献综述和现有关于COVID-19和肺高血压的研究的综合.
- 对将SARS-CoV-2感染与PH联系起来的拟议机制的分析.
- 讨论临床结果和治疗策略.
主要成果:
- 几个因素,包括细胞因子风暴,ARDS和纤维性肺部变化,都与COVID-19后PH风险增加有关.
- 诊断为COVID-19的先前存在PH的患者的结果需要进一步调查.
- 针对COVID-19心肺并发症的PH药物的非标签使用正在考虑中.
结论:
- COVID-19 存在发展肺高血压的潜在风险.
- 需要进一步的研究来澄清COVID-19在患有先前PH的患者的结果.
- 研究肺高血压疗法在治疗COVID-19并发症中的实用性具有前景.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
180
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
180
COPD: Pathogenesis and Clinical Features
273
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
273
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.8K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
214
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
214


